Comparison of oxcarbazepine metabolite concentrations measured by EMIT-based Siemens Viva-ProE® system and LC-MS/MS in Chinese patients
While uncorrected SVPS results exhibit a systematic bias that produces direct interchangeability with LC-MS/MS, applying a concentration-specific Deming correction enables clinically reliable TDM of MHD at concentrations below 22 μg/mL. However, method optimization is still required for accurate quantification in the high-concentration range.
Authors
- Xuemei Wu (ORCID: https://orcid.org/0000-0003-3442-324X)
- Yun-Yi Mao
- Rong-Qi Lin
- Junnan Wu (ORCID: https://orcid.org/0000-0002-0624-2057)
- Hongqiang Qiu (ORCID: https://orcid.org/0000-0003-3285-8768)
- Xueyong Li (ORCID: https://orcid.org/0000-0002-9022-5312)
- Yingbin Huang (ORCID: https://orcid.org/0009-0000-6617-7050)
- Yu Cheng (ORCID: https://orcid.org/0009-0002-5449-191X)
- Ming Chen
Institutions
- Fujian Medical University (CN)
- Shangri-la Institute (CN)
- Union Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-14
- DOI
- https://doi.org/10.3389/fphar.2025.1697679
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00